Epigenetic Regulation of Glycosylation in Cancer and Other Diseases

Rossella Indellicato 1,* and Marco Trinchera 2

1 Department of Health Sciences, University of Milan, 20142 Milan, Italy
2 Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy;
marco.trinchera@uninsubria.it
* Correspondence: rossella.indellicato@unimi.it

Abstract: In the last few decades, the newly emerging field of epigenetic regulation of glycosylation acquired more importance because it is unraveling physiological and pathological mechanisms related to glycan functions. Glycosylation is a complex process in which proteins and lipids are modified by the attachment of monosaccharides. The main actors in this kind of modification are the glycoenzymes, which are translated from glycosylation-related genes (or glycogenes). The expression of glycogenes is regulated by transcription factors and epigenetic mechanisms (mainly DNA methylation, histone acetylation and noncoding RNAs). This review focuses only on these last ones, in relation to cancer and other diseases, such as inflammatory bowel disease and IgA1 nephropathy. In fact, it is clear that a deeper knowledge in the fine-tuning of glycogenes is essential for acquiring new insights in the glycan field, especially if this could be useful for finding novel and personalized therapeutics.

Keywords: epigenetics; methylation; histone acetylation; miRNAs; glycosylation; glycogenes; cancer; inflammatory bowel disease; IgA nephropathy

1. Introduction

In the vast universe of cell biology, there is a very elaborate mechanism capable of carrying out a myriad of functions: glycosylation of proteins and lipids. It consists of the enzymatic attachment of monosaccharides to lipid or protein molecules [1], giving rise to a class of macromolecules called the glycoconjugates (glycoproteins, proteoglycans, mucins, glycosphingolipids, lipopolysaccharides). Glycoconjugates differ in their glycan (the carbohydrate chain) sequence, length, number and position of branches, and type of connections between sugars [1,2]. The complexity of glycan structures is due to the fact that glycan synthesis is not template-driven, unlike linear molecules such as DNA and proteins [3], and is influenced by many variables, including environmental factors, genetic factors (i.e., single nucleotide polymorphisms), transcription factors, protein transports, altered pH values in subcellular sites (especially in the Golgi apparatus), Golgi organizers, ion channels, oxygen concentration, subcellular localization of enzymes, activated monosaccharide donor substrates, and acceptor substrates availability [3–5]. In fact, it is estimated that more than 800 genes are involved in the process of glycosylation [6,7], and, among these, about 500 glycosylation-related genes (or glycogenes) are directly involved in glycan assembly, remodeling and degradation, and account for about 2% of the genome [8,9].

Glycosylation has important implications for numerous processes, including the following.

Physical and structural role: a dense layer of glycans (glycocalyx) covers the surface of all the cells allowing to modulate cell–cell, cell–matrix, and cell–molecule interactions, critical to the development of a complex multicellular organism [10,11]; protein folding [9]: it takes place in the endoplasmic reticulum and ensures protein stability and functioning [10]; transcriptional regulation [9,12]: O-GlcNAcylation participates in the epigenetic
regulation of gene expression [12–14]; interactions between host and pathogenic microorganism [10,11]; viruses and bacteria bind and get access to host cells through glycan receptors [15,16] and are able to evade the immune system decorating themselves with a layer of host-like glycans (the so-called “molecular mimicry” mechanism) [9,17]. Pathogens use another strategy to survive, called “glycan gimmickry”, consisting in targeting host–glycan-binding proteins with their glycans [18].

One of the most important features of glycosylation is that it takes place in a cell- and tissue-specific manner [3,6,19]. For example, it plays a very critical role in the development and function of the nervous system, where characteristic glycan structures regulate axon pathfinding, neurite outgrowth, synaptogenesis, neurotransmission, and other neuronal processes [20]. Moreover, neural-specific glycans are required to carry out high-order brain functions, including learning/memory and the formation of neural networks [6,21].

This review briefly describes the principal epigenetic mechanisms that participate in gene expression and how they are related to glycosylation. A short overview illustrates the normal physiology of epigenetic regulation of glycogenes, and a more extensive section is devoted to cancer and other diseases.

2. Epigenetic Regulation of Glycosylation

Since glycosylation is cell- and tissue-specific, but the DNA template is always the same in every cell of an organism, a master player able to regulate gene expression is required: epigenetics. It was defined as a “stably heritable phenotype resulting from changes in a chromosome without alterations in the DNA sequence” [22]. It is a process that takes place during the differentiation of somatic cells, as well as in response to environmental changes [23]. Epigenetics is one of the reasons why the cells of an organism have a different phenotype, even if they share the same DNA sequence. Epigenetics acts in order to regulate gene expression mainly through the following three mechanisms [24–28].

DNA methylation: it occurs in CpG rich-regions called CpG islands, where CpG dinucleotides tend to cluster. Frequently, methylation of these regions represses gene transcription and expression [29], while unmethylated regions promote gene activation. Basically, methylation requires a methyl group (CH$_3$) covalently attached to the 5-carbon of the cytosine residue (5mC) in the CpG site [26,30,31]. This action is carried out by DNA methyltransferases (DNMTs), and the CH$_3$ group physically interrupts the binding between the proper transcription factor and its recognition sequence. Moreover, gene silencing upon methylation can also occur when methyl-CpG-binding proteins bind to the methylated DNA and recruit co-repressor molecules, such as histone deacetylases, to induce chromatin structure condensation [32].

Histone modifications: the two main modifications that can occur on histones are methylation and acetylation. They alter chromatin structure; in fact, euchromatin (actively transcribed) is characterized by high levels of acetylation and di/trimethylation of H3K4, H3K36 and H3K79 [29,33], while heterochromatin (transcriptionally inactive) is characterized by low levels of acetylation and high levels of H3K9, H3K27 and H4K20 methylation [29]. O-GlcNAcylation is another form of histone modification [29,12–14], and it is the perfect example of how epigenetics and glycosylation are tangled together: epigenetics regulates glycogenes expression, and glycosylation participates in epigenetic regulation.

Noncoding RNAs (ncRNAs): a wide range of RNA molecules belongs to this category, which is included transfer RNA (tRNA), ribosomal RNA (rRNA), microRNA (miRNA), small interfering RNA (siRNA), piwi-interacting RNA (piRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), and long noncoding RNA (lncRNA) [34–36]. The most studied are miRNAs and lncRNAs. miRNAs are characterized by a short sequence of nucleotides (about 20–30), play a role in gene silencing [31] targeting mRNA 3’UTR regions, and inhibit protein translation or enhance mRNA degradation [26,34]. To date, over 80 glycogenes have been identified as miRNAs targets [37]. LncRNAs are longer than miRNAs (up to more than 100 kilobases) [25] and can function both by repressing or activating gene expression [34], acting as molecular chaperones or scaffolds for various chromatin regulators [31].
Of course, epigenetics is not the only mechanism involved in the transcription of glycogenes. In fact, also transcription factors binding to a gene promoter and enhancer elements are fundamental for this purpose [38]. A prominent example is given by transcription factors hepatocyte nuclear factor 1α (HNF1α) and its downstream target hepatocyte nuclear factor 4α (HNF4α), which were proven by Lauc et al. in the first genome-wide association study (GWAS) of protein glycosylation to regulate the expression of key fucosyltransferases and fucose biosynthesis genes. This finding revealed a new role for HNF1α as a master transcriptional regulator of multiple stages in the fucosylation process [39].

3. Physiological Aspects of Epigenetic Regulation of Glycosylation

Before going deeper into the field of epigenetic regulation associated with pathological glycosylations, it is worth making a brief presentation on how glycogenes are regulated by epigenetics when it comes to normal physiology. Research in this field is just at the beginning, and there are little available data at present. Yet, some prominent studies carried out on the brain elucidated the significance/importance of specific neural glycans since their fine-tuning is pivotal for high-order brain functions (i.e., learning/memory, the formation of the neural network, myelination), and their dysregulation leads to various neurological disorders [40].

The first research group focused on a glycosyltransferase called N-acetylglucosaminyltransferase IX (MGAT5B), that catalyzes the transfer of N-acetylglucosamine (GlcNAc) to the 6-OH position of the mannose residues of GlcNAcβ1,2-Mana on both the α1,3- and α1,6-linked mannose arms in the core structure of N-glycans. It is also responsible for the transfer of GlcNAc in β1,6-linkage to O-mannosyl glycans. The gene encoding this enzyme is MGAT5B, which is exclusively expressed in the brain [41], and it has been proved that it is under the control of neural cell-specific histone modification: active chromatin marks like H3K9ac and H3K4me3 were found in the mouse brain, and repressive chromatin marks like H3K27me3 and H3K9me2 were detected in mouse kidney and liver [42].

The second research group studied two glycosyltransferases involved in lipid glycosylation: B4GALNT1 and ST8SIA1. They are both involved in the biosynthesis of gangliosides, a class of sialic acid-containing glycosphingolipids particularly abundant in the central nervous system. Their peculiarity consists in being ontogenically regulated, and in fact, they are more expressed in the adult brain. Experiments on mice showed that brain gangliosides shift from the simpler ones (GM3 and GD3) in early phases of life to more complex ones during development (GM1, GD1a, GT1a, and GT1b) and that expression of B4galnt1 (prevalently) and St8Sia1, both involved in this shifting, increased, due to histone H3 and H4 acetylation [43–45].

4. Epigenetic Regulation of Glycosylation in Cancer

The majority of the studies of epigenetic regulation of glycogenes are about cancer. It is well-established that aberrant glycosylation is one of the hallmarks of tumoral cells [46–48] and that these changes are nonrandom: in cancer advancement, only the fittest cells survive, and specific glycan changes are selected for tumor progression [47]. In fact, transcription of a gene tends to be constitutively repressed in cancer, when its epigenetic silencing is advantageous for promoting cancer progression [49]. In particular, incomplete synthesis and neo-synthesis processes are the two principal mechanisms associated with alterations of carbohydrate structures during tumor progression [50]. Incomplete synthesis refers to truncated glycosylation that produces the Tn antigen in mucin-type O-glycans, and neo-synthesis produces abnormal glycosylation patterns such as sialyl Lewis X (sLex) [51,52]. Tn antigen and sLex are typical of lymphocytes and help in their extravasation from the blood, while in cancer, they facilitate metastatic spread [1,53]. Novel glycan structures also have the role of enabling cancer cells to evade the host immune response [15,51,54,55].

All these modifications in glycosylation during the tumoral event are carried out by genetic, epigenetic, metabolic, inflammatory and environmental mechanisms [52], but this review focuses only on epigenetic alterations that affect glycogenes during carcinogenesis. The first studies were based on the methylation status of the promoter region, using
demethylating agents such as 5-aza-2-deoxycytidine (5-aza-dC) [56–58]. Later on, it was discovered that hypermethylation of a promoter could not be sufficient to maintain gene silencing; in fact, even upon a treatment, only a partial restoration was achieved, and this was due to other epigenetic marks involved such as repressive histone modifications [59,60].

Epigenetic modifications of glycogenes in cancer were extensively reviewed by Dall’Olio and Trinchera [48], and the most recent ones are updated in Table 1, but it is most likely that the number of glycogenes epigenetically regulated in cancer is going to grow in the next years.

Table 1. List of glycogenes regulated through epigenetics.

| Target       | Epigenetic Mechanism | Effect                | Tissue/Cells Involved                                                                 | References  |
|--------------|----------------------|-----------------------|--------------------------------------------------------------------------------------|-------------|
| **Galactosyltransferases** |                      |                       |                                                                                      |             |
| B4GALT3      | miR-1247-3p          | Downregulation        | CAFs in lung metastasis of liver cancer                                              | [61,62]     |
|              | CircUBXN7/miR-1247-3p| Upregulation          | Bladder cancer                                                                       |             |
| GALNT1       | LncRNA SNHG7/miR-216b| Upregulation          | Colorectal cancer                                                                     | [63]        |
| GALNT3       | Linc01296/miR-26a    | Upregulation          | Colorectal cancer                                                                     | [64]        |
| GALNT4       | miR-4262 (downregulated) | Upregulation      | Colorectal cancer                                                                     | [65]        |
| GALNT7       | miR-30e (downregulated) | Upregulation          | Cervical cancer                                                                       | [66–69]     |
|              | LncRNA SNHG7/miR-34a | Upregulation          | Colorectal cancer                                                                       |             |
|              | miR-154 (downregulated) | Upregulation          | Laryngeal squamous cell carcinoma                                                     |             |
|              | miR-125a-5p (downregulated) | Upregulation         | Cervical cancer                                                                       |             |
| GALNT14      | Hypermethylation     | Downregulation        | A549-T cells (paclitaxel-resistant strain of human non-small cell lung cancer)       | [70]        |
| **N-acetyl-galactosaminyl transferases** |                      |                       |                                                                                      |             |
| MGAT3        | miR-23a (upregulated)| Downregulation        | Hca-P (mouse) cell line                                                               | [73]        |
| OGT          | miR-24-1 (downregulated) | Upregulation          | Hca-F (mouse) cell line                                                               |             |
|              | miR-24 (downregulated) | Upregulation          | High invasive breast cancer cell lines                                               | [74–78]     |
|              | miR-483 (downregulated) | Upregulation          | Gastric cancer                                                                       |             |
|              | miR-485-5p (downregulated) | Upregulation          | Colorectal cancer and esophage cancer cell lines                                     |             |
| **Sialyltransferases** |                      |                       |                                                                                      |             |
| ST3GAL4      | miR-370 (treatment)  | Downregulation        | Colo 320 cell line                                                                   | [79]        |
| ST6GAL1      | miR-9 (downregulated) | Upregulation          | Hepatocellular carcinoma cell lines with high lymphatic metastatic potential         | [80–82]     |
|              | LncRNA ZFAS1/miR-150| Upregulation          | T-cell acute lymphoblastic leukemia                                                  |             |
|              | LncRNA HOTAIR/miR-214| Upregulation          | Colorectal cancer                                                                     |             |
| ST6GAL2      | LncRNA HCP5/miR-22-3p, miR-186-5p, miR-216a-5p axis | Upregulation          | Follicular thyroid carcinoma                                                          | [83]        |
Below, we present some prominent examples of epigenetically modified glycogenes involved in tumor progression.

### 4.1. C1GALT1C1

One of the hallmarks of carcinoma mucins is their incomplete glycosylation. The addition of the first N-acetylgalactosamine (GalNAc) O-linked to serine or threonine of mucin-type glycans leads to the formation of the Tn antigen, which is a well-known cancer-associated structure [48]. On this first GalNAc, a Gal residue could be added by core 1 \( \beta \)1,3-galactosyltransferase (C1GALT1 or T-synthase), which needs the molecular chaperone C1GALT1C1 (encoded by C1GALT1C1 gene) for its functioning. This leads to the formation of the T antigen. At the same time, another enzyme called sialyltransferase ST6GALNAC1 could act on the Tn antigen, adding a residue of \( \alpha \)2,6-linked sialic acid, resulting in the formation of the sialyl-Tn (STn) antigen and blocking further chain elongation [52,104]. During carcinogenesis, C1GALT1C1 expression could be downregulated due to genetic mutations [105] or, more interestingly, to an epigenetic modification: hypermethylation of the promoter leads to the silencing of C1GALT1C1 and to the accumulation of the cancer-associated Tn and STn antigens [106,107]. The secreted mucins expressing these antigens often appear in the bloodstream of patients with cancer and are associated with invasion since they potentiate migration of tumor cells through the inhibition of cell–cell

### Table 1. Cont.

| Target       | Epigenetic Mechanism | Effect             | Tissue/Cells Involved | References |
|--------------|----------------------|--------------------|-----------------------|------------|
| ST6GALNAC2   | miR-182 and miR-135b | Downregulation     | Colorectal cancer     | [84]       |
| ST6GALNAC3   | Promoter hypermethylation | Downregulation     | Prostate cancer       | [85]       |
| ST6GALNAC5   | Promoter hypermethylation | Downregulation     | Cervical cancer       | [86]       |
| ST6GALNAC6   | Histone methylation (H3K27me3) | Downregulation     | Colon cancer          | [87]       |
| ST8SIA1      | miR-33a and let-7e (downregulated) | Not evaluated     | Triple-negative breast cancer, Esophageal cancer | [88–90] |
| ST8SIA4      | miR-146a and miR-146b (upregulated) | Downregulation     | Follicular thyroid carcinoma, Oral squamous carcinoma cell lines | [91,92] |

#### Fucosyltransferases

| FUT1         | miR-34a (downregulated) | Upregulation        | Head and neck squamous cell carcinoma | [93]       |
|--------------|-------------------------|---------------------|---------------------------------------|------------|
| FUT4         | miR-26a e miR-26b (downregulated) | Upregulation     | Colorectal cancer, Breast cancer, Bladder cancer cell lines, MCF-7 cell line (breast cancer) | [94–100] |
|              | miR-200b (downregulated) | Upregulation        | Cholangiocarcinoma, Acute myeloid leukemia, Bladder cancer cell lines |
|              | miR-125a-5p (downregulated) | Upregulation        |                                      |
|              | miR-200c (treatment)    | Downregulation      |                                      |
|              | miR-1295b and miR-6715amIR-29b/Sp1 axis | Not evaluated     |                                      |
|              | LncRNA AC114812.8/miR-371b-5p axis | Upregulation     |                                      |
| FUT5         | miR-125a-3p (downregulated) | Upregulation        | Colorectal cancer                   | [101]      |
| FUT6         | miR-125a-3p (downregulated) | Upregulation        | Colorectal cancer                   | [101,102] |
|              | LncRNA HOTAIR/miR-326 axis | Upregulation        |                                      |

#### Sulfotransferases

| HS3ST3B1     | miR-218 (downregulated) | Upregulation        | Non-small cell lung cancer         | [103]      |

#### Nucleotide donor transporters

| DTDST        | Histone methylation (H3K27me3) | Downregulation     | Colon cancer                       | [87]       |
contacts [108,109]. Moreover, these carcinoma mucins often decorate the tumor surface, creating clustered sites for antibody attachment, thereby improving their activity as tumor immunogens. In fact, since these glycans infrequently occur in normal tissues, they provoke immune responses in patients, a property that has been exploited for potential immunotherapy [47,108].

4.2. B4GALNT2 (β-1,4-N-acetyl-galactosaminyltransferase 2)

Sda carbohydrate (GalNAcβ1,4[Sia]α2,3Galβ1,4GlcNAc) belongs to the category of the histo-blood group antigens. They were initially found on the erythrocyte surface, but it was soon discovered that this group of antigens is widely distributed in many epithelial tissues (colon, stomach, kidney, oocyte) and secretions (urine, serum, saliva, milk) [110–112], and play roles in the regulation of physiological mechanisms. In particular, studies in murine models showed that the Sda antigen is involved in the processes of hemostasis [113,114] and reproduction [115,116]. The last step in the biosynthesis of the Sda antigen is catalyzed by GalNAc transferase B4GALNT2 (also known as Sda synthase), which adds an N-acetylgalactosamine to a terminal α2,3-sialylated galactose residue [117]. Experiments on guinea-pigs [118] and rats [119] proved that the B4GALNT2 gene could be ontogenically regulated; in fact, the enzyme was absent at birth and increased with age. More information on Sda synthase is known as far as concern cancer since the expression and activity of this enzyme are downregulated in gastrointestinal cancer leading to a complete loss of the antigen [112,117,120]. The reason for such differential expression was attributed to the hypermethylation of the B4GALNT2 promoter [120,121], which is embedded in CpG islands. In work by Kawamura et al. [54], the B4GALNT2 gene was found methylated in about one-half of the gastric cancer cases taken under consideration and in the majority of gastric and colon cancer cell lines. They used a demethylating agent, 5-aza-dC, to attempt a recovery of B4GALNT2 transcription, but it worked only partially, inducing a very weak expression of both the glycoenzyme and the Sda antigen. Human colon cancer cells were also treated with the histone acetylase inhibitor butyrate, but neither a slight recovery of the Sda antigen nor that of B4GALNT2 was observed. According to these results, the mechanism of B4GALNT2 downregulation in cancer deserves further investigation [122].

4.3. B3GALT5

B3GALT5 is one of the glycoenzymes involved in the synthesis of type 1 chain carbohydrate antigens, namely the Lewis a (Lea) trisaccharide, the Lewis b (Leb) tetrasaccharide and the sialyl Lewis a (sLea) tetrasaccharide [123,124]. Lea and Leb are involved in various biological contexts, such as microbial adhesion and cancer [125], whereas sLea has been proven to be specifically an E-selectin ligand, favoring the metastatic process and angiogenesis during cancer development [124,126,127]. The peculiarity of B3GALT5 is that its expression is regulated by two promoters: the LTR and native promoters [128].

The LTR promoter, which has retroviral origins and is activated through hepatocyte nuclear factor HNF1α and HNF1β [129,130], is mainly active in the organs of the gastrointestinal tract (such as the colon, stomach, and pancreas). However, HNF1α and HNF1β are not able to modulate transcription, which depends on distal regulatory elements that are active when methylated. In fact, LTR and proximal sequences lack CpG islands, suggesting that methylation-sensitive DNA sequences reside outside the LTR region, presumably distant from the promoter, where they act as potential epigenetic regulators of transcription [130,131].

In the mammary glands, thymus and trachea, as well as in some human cancer cell lines, transcription is mainly driven by a native promoter, which is sensitive to nuclear factor NF-Y [124] and is located nearby two CpG islands [132] epigenetically regulated through methylation [130]. As for the LTR promoter, NF-Y is unable to regulate transcription, which depends on the methylation of the regulatory elements [130,131]. Moreover, histone modification is another mechanism involved in the regulation. High expression
of the native transcript is associated with active histone marks (H3K4me3, H3K79me2, H3K9Ac, and H3K9-14Ac), while low levels of the transcript are associated with repressive histone marks (H3K27me2 and H4K20me3) [132].

The differential regulation of B3GALT5 was studied in particular in the pancreas and colon, comparing normal and tumoral tissues [130–132]. B3GALT5 is strongly downregulated in colon cancer with respect to the normal mucosa [133,134], and the silencing of the gene is due to the opposite but synergic behavior of the two promoters: hypomethylation of the distant sequences of the LTR promoter and hypermethylation of the native promoter [124]. In the pancreas, both normal and cancer tissues have very low levels of methylation in the native promoter, and the levels of B3GALT5 LTR transcript were similar to those of the native transcript, without difference between normal and tumoral specimens [131,132].

5. Epigenetic Regulation of Glycosylation in Other Diseases

Dysregulation of glycosylation is associated not only with cancer but also with a number of other diseases. The majority of them are caused by genetic mutations such as congenital disorders of glycosylation, diabetes, cardiovascular, immunological, autoimmune (rheumatoid arthritis, Sjögren’s syndrome, systemic lupus erythematosus) and infectious disorders [2,7]. Other diseases are associated with both genetic and epigenetic modifications, such as inflammatory bowel disease (IBD), IgA1 nephropathy (IgAN), and neurodegenerative diseases, briefly reviewed below. Since this is a recent field of research, it is highly probable that the disorders associated with aberrant epigenetic regulation of glycosylation will increase over time, giving a better insight into the disease pathogenesis.

5.1. Inflammatory Bowel Disease

IBD is a chronic inflammatory disorder that affects the gastrointestinal tract and comprises two clinical syndromes: Crohn’s disease (CD) and ulcerative colitis (UC) [135,136]. These diseases have unknown etiology, and there is insufficient information about pathogenesis, but it is believed that a complex interaction of genetic, epigenetic, microbial, environmental and immunological factors are involved [137]. In particular, several studies have evaluated the epigenetic status of IBD patients using candidate gene strategies [138–142] or epigenome-wide association studies [143–146], trying to elucidate IBD pathogenesis [147]. Cooke and colleagues [143] collected rectal biopsies and identified some glycogenes that have a differential methylation status between patients with CD and UC (inflamed vs. non-inflamed) and healthy controls. In fact, in inflamed UC vs. controls, B3GALT2, GFPT1 and GBGT1 have increased methylation; in inflamed CD vs. controls, GFPT1 and GBGT1 have increased methylation and FUT2 has a decreased methylation; in non-inflamed CD vs. controls, FUT7 and FGF23 have decreased methylation. These altered methylation levels correlated with the development of IBD, contributing to better understand IBD pathogenesis. Another study conducted by Klasic and colleagues evaluated the methylation status of β-1,4-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase (MGAT3) promoter in CD3⁺ T cells isolated from the inflamed mucosa of UC patients. They found that the MGAT3 promoter was hypermethylated in UC patients compared with healthy controls. This kind of deregulation might lead to an increase of the proinflammatory properties of IgG through a decrease in galactosylation and sialylation and an increase of bisecting GlcNAc on digalactosylated glycans, thus suggesting a functional role of MGAT3 in IBD pathogenesis [148].

5.2. IgA1 Nephropathy

Several studies led to the conclusion that inhibition of genes involved in glycosylation by miRNAs plays a role in the pathogenesis of IgA1 nephropathy (IgAN), which is characterized by the aggregation of aberrantly glycosylated IgA1 molecules, leading to the synthesis of inflammatory cytokines and glomerulonephritis. The first study conducted by Serino and colleagues brought to the attention the role of miR-148b. It was demonstrated
that peripheral blood mononuclear cells (PBMCs) of patients with IgAN show a higher miR-148b expression level compared to healthy controls, and this upregulation leads to a lower C1GALT1 expression. C1GALT1 is involved in the O-glycosylation of the IgA1 heavy chain hinge-region, and without the expression of the gene, hinge-region displays a deficiency of galactose [149]. This group also demonstrated that GALNT2 (UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase 2) is the target of miRNA let-7b, similarly to C1GALNT1 and miR-148b. GALNT2 initiates the addition of GalNAc to serine or threonine residues of the IgA1 hinge-region. Let-7b was significantly upregulated in IgAN patients, and, as a consequence, GALNT2 levels became lower [150].

Recently, another miRNA was found to be involved in the aberrant glycosylation of IgAN, but not in a direct way. In fact, the direct target of miR-98–5p is CCL3 (C–C motif chemokine ligand 3), which can change the level of Th1 and Th2 cytokines in many diseases. Th1 and Th2 cytokines participate in the pathogenesis of IgAN. In this case, only IL-6 was found to be upregulated in PBMCs of IgAN patients compared to healthy controls. IL-6 reduces the galactosylation of IgA1 by decreasing the expression of C1GALT1 [151].

Another miRNA able to indirectly modify glycosylation in IgAN is miR-374b. The target of this miRNA is C1GALT1C1, which is required for the activity of C1GALT1, and that is downregulated in the B cells isolated from IgAN patients, leading to abnormal glycosylation of IgA1 [152]. Furthermore, miR-320 (upregulated in the renal tissues of IgAN patients) targets C1GALT1C1, which in fact is downregulated in the same patients [67].

5.3. Neurodegenerative Diseases

A critical role of glycosylation is emerging in the field of neuron homeostasis and related neurodegenerative diseases. It is well-known that several glycoconjugates and related processing enzymes, namely glycosyltransferases and glycosidases, are strictly and specifically expressed in the central nervous system, and a set of specific glycosylations, such as ganglioside biosynthesis and GlcNAcylation, are strongly associated with various neurodegenerative disorders [153]. At present, the majority of data arise from genetic defects. Both KO mice of ganglioside glycosyltransferases and congenital disorders of glycosylation affecting ganglioside biosynthesis indicated that ganglioside dysregulation gives rise to neuroinflammation, functional impairment, and in turn neurodegeneration [153,154]. Moreover, non-genetic derangement of glycosyltransferases was associated with Parkinson’s disease (reduced B3GALT4 and ST3GAL2, increased OGT, O-linked GlcNAc transferase), Huntington disease (reduced ST3GAL5, ST3GAL2, ST8SIA3, B4GALNT1), Alzheimer’s disease, and even amyotrophic lateral sclerosis (general ganglioside overexpression) [153,155]. In multiple sclerosis, an autoimmune disease causing inflammation of the central nervous system, glycoproteins are candidate targets of autoreactivity, and glycosyltransferases such as MGAT1, MGAT5 and B4GALNT6 are reported as deregulated genes [7,156]. A key role of epigenetic regulation is reported in multiple sclerosis [7] and suggests that such mechanism could be the common trait of some of the other neurodegenerative disorders associated with deranged glycosylation.

6. Concluding Remarks

Epigenetic regulation of glycosylation is an emerging and relatively recent field of research. The analysis of glycogenes expression due to epigenetic mechanisms started with the use of demethylating agents in cancer cell cultures [57,157], and it has become more important over the years. At present, several pathological mechanisms associated with cancer and other diseases are known to be caused by epigenetic dysregulation of glycosylation, as reported in this review. We also reported relevant studies illustrating how epigenetics controls glycosylation under physiological conditions [3,6,44,45,122,158,159]. Altogether these findings help to unravel the roles and functions of glycans, which are candidate targets in the field of personalized medicine through drugs-based inhibitors of their synthesis, glycan antagonists, and glycan-function modulators [52]. In this regard, it is also worth recalling the critical interplays involving glycosylation, epigenetics, and
hypoxia since one controls the other. This suggests that drugs affecting glycosylation through epigenetic regulation could be relevant in cancer developing chemo-resistance [26].

**Funding:** This research was supported by “Aldo Ravelli” Center for Neurotechnology and Experimental Brain Therapeutics (M.T.) and from the University of Insubria (to M.T.). R.I. was supported by the PhD program in Translational Medicine of the University of Milan. The APC was funded by the University of Milan “Biblioteca digitale” (to R.I.).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Abbreviations**

Genes and proteins are named according to the HUGO recommendations.

- 5-aza-dC 5-Aza-2-deoxycytidine
- B3GALT5 β1,3-Galactosyltransferase isoenzyme 5
- B4GALNT2 β-1,4-N-Acetylgalactosaminyltransferase 2
- C1GALT1 Core 1 β1,3-galactosyltransferase
- C1GALT1C1 C1GALT1-specific chaperone 1
- CAF Cancer-associated fibroblast
- CD Crohn’s disease
- FGF23 Fibroblast growth factor 23
- GalNAc N-Acetylgalactosamine
- GBGT1 Globoside α-1,3-N-Acetylgalactosaminyltransferase 1
- GALNT2 UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase 2
- GFPT1 Glutamine-fructose-6-phosphate transaminase 1
- GlcNAc N-Acetylgalosamine
- HNF1α Hepatocyte nuclear factor 1α
- HNF4α Hepatocyte nuclear factor 4α
- IBD Inflammatory bowel disease
- IgAN IgA1 nephropathy
- MGAT3 β-1,4-Mannosyl-glycoprotein 4-β-N-acetylgalcosaminyltransferase
- OGT O-Linked GlcNAc transferase
- PBMC Peripheral blood mononuclear cell
- lncRNA Long noncoding RNA
- miRNA MicroRNA
- ncRNA Noncoding RNA
- piRNA Piwi-interacting RNA
- rRNA Ribosomal RNA
- siRNA Small interfering RNA
- snoRNA Small nucleolar RNA
- tRNA Transfer RNA
- sLex Sialyl Lewis X
- UC Ulcerative colitis

**References**

1. Reily, C.; Stewart, T.J.; Renfrow, M.B.; Novak, J. Glycosylation in health and disease. *Nat. Rev. Nephrol.* 2019, 15, 346–366. [CrossRef]
2. Lauc, G.; Zoldos, V. Protein glycosylation—An evolutionary crossroad between genes and environment. *Mol. Biosyst.* 2010, 6, 2373–2379. [CrossRef] [PubMed]
3. Lauc, G.; Vojta, A.; Zoldos, V. Epigenetic regulation of glycosylation is the quantum mechanics of biology. *Biochim. Biophys. Acta* 2014, 1840, 65–70. [CrossRef] [PubMed]
4. Klastic, M.; Kristic, J.; Horvat, T.; Markulin, D.; Vejta, A.; Reiding, K.R.; Wuhmer, M.; Lauc, G.; Zoldos, V. DNA hypomethylation upregulates expression of the MGAT3 gene in HepG2 cells and leads to changes in N-glycosylation of secreted glycoproteins. *Sci. Rep.* 2016, 6, 24363. [CrossRef] [PubMed]

5. Nairn, A.V.; York, W.S.; Harris, K.; Hall, E.M.; Pierce, J.M.; Moremen, K.W. Regulation of glycan structures in animal tissues: Transcript profiling of glycan-related genes. *J. Biol. Chem.* 2008, 283, 17298–17313. [CrossRef] [PubMed]

6. Kizuka, Y.; Kitazume, S.; Okahara, K.; Villagra, A.; Sotomayor, E.M.; Taniguchi, N. Epigenetic regulation of a brain-specific glycosyltransferase N-acetylglucosaminyltransferase-IX (GnT-IX) by specific chromatin modifiers. *J. Biol. Chem.* 2014, 289, 11253–11261. [CrossRef]

7. Stambuk, T.; Klastic, M.; Zoldos, V.; Lauc, G. N-glycans as functional effectors of genetic and epigenetic disease risk. *Mol. Aspects Med.* 2020, 100891. [CrossRef]

8. Ng, B.G.; Freeze, H.H. Perspectives on Glycosylation and Its Congenital Disorders. *Trends Genet.* 2018, 34, 466–476. [CrossRef]

9. Springer, S.A.; Gagneux, P. Glycan evolution in response to collaboration, conflict, and constraint. *J. Biol. Chem.* 2013, 288, 6904–6911. [CrossRef]

10. Varki, A. Biological roles of glycans. *Glycobiology* 2017, 27, 3–49. [CrossRef]

11. Varki, A.; Kornfeld, S. Historical Background and Overview. In *Essentials of Glycobiology*, 3rd. ed.; Varki, A.C.R., Esko, J.D., Eds.; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, USA, 2015; Chapter 1. [CrossRef]

12. Hanover, J.A.; Krause, M.W.; Love, D.C. Bittersweet memories: Linking metabolism to epigenetics through O-GlcNAcylation. *Nat. Rev. Mol. Cell Biol.* 2012, 13, 312–321. [CrossRef]

13. Leturcq, M.; Lefebvre, T.; Verrouet-Edouart, A.S. O-GlcNAcylation and chromatin remodeling in mammals: An up-to-date overview. *Biochem. Soc. Trans.* 2017, 45, 323–338. [CrossRef]

14. Lewis, B.A.; Hanover, J.A. O-GlcNAc and the epigenetic regulation of gene expression. *J. Biol. Chem.* 2014, 289, 34440–34448. [CrossRef]

15. Lauc, G.; Zoldos, V. Epigenetic regulation of glycosylation could be a mechanism used by complex organisms to compete with microbes on an evolutionary scale. *Med. Hypotheses* 2009, 73, 510–512. [CrossRef] [PubMed]

16. Varki, A.; Gagneux, P. Biological Functions of Glycans. In *Essentials of Glycobiology*, 3rd. ed.; Varki, A.C.R., Esko, J.D., Eds.; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, USA, 2015; Chapter 7; pp. 77–88. [CrossRef] [PubMed]

17. Corfield, A.P.; Berry, M. Glycan variation and evolution in the eukaryotes. *Trends Biochem. Sci.* 2015, 40, 351–359. [CrossRef] [PubMed]

18. Van Die, I.; Cummings, R.D. Glycan gimmickry by parasitic helminths: A strategy for modulating the host immune response? *Glycobiology* 2010, 20, 2–12. [CrossRef]

19. Moremen, K.W.; Tiemeyer, M.; Nairn, A.V. Vertebrate protein glycosylation: Diversity, synthesis and function. *Nat. Rev. Mol. Cell Biol.* 2012, 13, 448–462. [CrossRef] [PubMed]

20. Williams, S.E.; Mealer, R.G.; Scolnick, E.M.; Smoller, J.W.; Cummings, R.D. Aberrant glycosylation in schizophrenia: A review of 25 years of post-mortem brain studies. *Mol. Psychiatry* 2020, 25, 3198–3207. [CrossRef] [PubMed]

21. Weinhold, B.; Seidenfaden, R.; Rockle, I.; Muhlenhoff, M.; Schertzinger, F.; Conzelmann, S.; Marth, J.D.; Gerardy-Schahn, R.; Hildebrandt, H. Genetic ablation of polysialic acid causes severe neurodevelopmental defects rescued by deletion of the neural cell adhesion molecule. *J. Biol. Chem.* 2005, 280, 42971–42977. [CrossRef] [PubMed]

22. Berger, S.L.; Kouzarides, T.; Shiekhattar, R.; Shilatifard, A. An operational definition of epigenetics. *Genes Dev.* 2009, 23, 781–783. [CrossRef] [PubMed]

23. Lind, M.I.; Spagoupolou, F. Evolutionary consequences of epigenetic inheritance. *Heredity* 2018, 121, 205–209. [CrossRef] [PubMed]

24. Bannister, A.J.; Kouzarides, T. Regulation of chromatin by histone modifications. *Cell Res.* 2011, 21, 381–395. [CrossRef]

25. Cavalli, G.; Heard, E. Advances in epigenetics link genetics to the environment and disease. *Nature* 2019, 571, 489–499. [CrossRef] [PubMed]

26. Grevelle, G.; Heard, E. Advances in epigenetics link genetics to the environment and disease. *Nature* 2019, 571, 489–499. [CrossRef] [PubMed]

27. Tsai, Y.T.; Yu, R.K. Epigenetic activation of mouse ganglioside synthase genes: Implications for neurogenesis. *J. Neurochem.* 2014, 128, 101–110. [CrossRef] [PubMed]

28. Zoldos, V.; Horvat, T.; Novokmet, M.; Cuenin, C.; Muzinic, A.; Pucic, M.; Huffman, J.E.; Gornik, O.; Polasek, O.; Campbell, H.; et al. Epigenetic silencing of HNF1A associates with changes in the composition of the human plasma N-glycome. *Epigenetics* 2012, 7, 164–172. [CrossRef]

29. Portela, A.; Esteller, M. Epigenetic modifications and human disease. *Nat. Biotechnol.* 2010, 28, 1057–1068. [CrossRef]

30. Skvortsova, K.; Iovino, N.; Bogdanovic, O. Functions and mechanisms of epigenetic inheritance in animals. *Nat. Rev. Mol. Cell Biol.* 2018, 19, 774–790. [CrossRef]

31. Dawson, M.A.; Kouzarides, T. Cancer epigenetics: From mechanism to therapy. *Cell* 2012, 150, 12–27. [CrossRef]

32. Oda, S.; Fukushima, T.; Yokoi, T.; Nakajima, M. Epigenetic regulation is a crucial factor in the repression of UGT1A1 expression in the human kidney. *Drug Metab. Dispos.* 2013, 41, 1738–1743. [CrossRef]
33. Norouzitallah, P.; Baruah, K.; Vanrompay, D.; Bossier, P. Can epigenetics translate environmental cues into phenotypes? *Sci. Total Environ.* 2019, 647, 1281–1293. [CrossRef]

34. Hombach, S.; Kretz, M. Non-coding RNAs: Classification, Biology and Functioning. *Adv. Exp. Med. Biol.* 2016, 937, 3–17. [CrossRef][PubMed]

35. Huttenhofer, A.; Schattner, P.; Polacek, N. Non-coding RNAs: Hope or hype? *Trends Genet.* 2005, 21, 289–297. [CrossRef]

36. Wei, J.W.; Huang, K.; Yang, C.; Kang, C.S. Non-coding RNAs as regulators in epigenetics (Review). *Oncol. Rep.* 2017, 37, 3–9. [CrossRef][PubMed]

37. Thu, C.T.; Mahal, L.K. Sweet Control: MicroRNA Regulation of the Glycome. *Biochemistry* 2020, 59, 3098–3110. [CrossRef][PubMed]

38. Neelamegham, S.; Mahal, L.K. Multi-level regulation of cellular glycosylation: From genes to transcript to enzyme to structure. *Curr. Opin. Struct. Biol.* 2016, 40, 145–152. [CrossRef]

39. Lauc, G.; Essafi, A.; Huffman, J.E.; Hayward, C.; Knezevic, A.; Kattla, J.J.; Polasek, O.; Gornik, O.; Vitart, V.; Abrahams, J.L.; et al. Genomics meets glycomics—the first GWAS study of human N-Glycome identifies HNF1alpha as a master regulator of plasma protein fucosylation. *PLoS Genet.* 2010, 6, e1001256. [CrossRef]

40. Kizukzu, Y.; Nakano, M.; Miura, Y.; Taniguchi, N. Epigenetic regulation of neural N-glycomics. *Proteomics* 2016, 16, 2854–2863. [CrossRef]

41. Inamori, K.; Endo, T.; Gu, J.; Matsuo, I.; Ito, Y.; Fuji, S.; Iwasaki, H.; Narimatsu, H.; Miyoshi, E.; Honke, K.; et al. N-Acetylglucosaminyltransferase IX acts on the GlcNAc beta 1,2-Man alpha 1-Ser/Thr moiety, forming a 2,6-branched structure in brain O-mannosyl glycan. *J. Biol. Chem.* 2004, 279, 2337–2340. [CrossRef]

42. Kizukzu, Y.; Kitazume, S.; Yoshida, M.; Taniguchi, N. Brain-specific expression of N-acetylglucosaminyltransferase IX (GnT-IX) is regulated by epigenetic histone modifications. *J. Biol. Chem.* 2011, 286, 31875–31884. [CrossRef][PubMed]

43. Itokazu, Y.; Tsai, Y.T.; Yu, R.K. Epigenetic regulation of ganglioside expression in neural stem cells and neuronal cells. *Glycoconj. J.* 2017, 34, 749–756. [CrossRef]

44. Itokazu, Y.; Wang, J.; Yu, R.K. Gangliosides in Nerve Cell Specification. *Prog. Mol. Biol. Transl. Sci.* 2018, 156, 241–263. [CrossRef]

45. Suzuki, Y.; Yanagisawa, M.; Ariga, T.; Yu, R.K. Histone acetylation-mediated glycosyltransferase gene regulation in mouse brain during development. *J. Neurochem.* 2011, 116, 874–880. [CrossRef]

46. Tuccillo, F.M.; de Laurentiis, A.; Palmieri, C.; Fiume, G.; Bonelli, P.; Borrelli, A.; Tassone, P.; Scala, I.; Buonaguro, F.M.; Quinto, I.; et al. aberrant glycosylation as biomarker for cancer: Focus on CD43. *BioMed Res. Int.* 2014, 2014, 742831. [CrossRef]

47. Varki, A.; Kannagi, R.; Toole, B.; Stanley, P. Glycosylation Changes in Cancer. In *Essentials of Glycobiology*, 3rd. ed.; Varki, A., Cummings, R.D., Esko, J.D., Stanley, P., Hart, G.W., Aebi, M., Darvill, A.G., Kinoshita, T., Packer, N.H., Eds.; Cold Spring Harbor Press: Cold Spring Harbor, NY, USA, 2015; pp. 597–609, Chapter 47. [CrossRef]

48. Dall’Olio, F.; Trinchera, M. Epigenetic Bases of Aberrant Glycosylation in Cancer. *Int. J. Mol. Sci.* 2017, 18, 998. [CrossRef][PubMed]

49. Kannagi, R.; Sakuma, K.; Miyazaki, K.; Lim, K.T.; Yusa, A.; Yin, J.; Izawa, M. Altered expression of glycan genes in cancers induced by epigenetic silencing and tumour hypoxia: Clues in the ongoing search for new tumor markers. *Cancer Sci.* 2010, 101, 586–593. [CrossRef][PubMed]

50. Hakomori, S.; Kannagi, R. Glycosphingolipids as tumor-associated and differentiation markers. *J. Natl. Cancer Inst.* 1983, 71, 21.

51. Kannagi, R.; Yin, J.; Miyazaki, K.; Izawa, M. Current relevance of incomplete synthesis and neo-synthesis for cancer-associated alteration of carbohydrate determinants—Hakomori’s concepts revisited. *Biochim. Biophys. Acta* 2007, 1777, 305–309. [CrossRef][PubMed]

52. Pinho, S.S.; Reis, C.A. Glycosylation in cancer: Mechanisms and clinical implications. *Nat. Rev. Cancer* 2015, 15, 540–555. [CrossRef][PubMed]

53. Magalhaes, A.; Duarte, H.O.; Reis, C.A. Aberrant Glycosylation in Cancer: A Novel Molecular Mechanism Controlling Metastasis. *Cancer Cell* 2017, 31, 733–735. [CrossRef]

54. Kawamura, Y.I.; Toyota, M.; Kawashima, R.; Hagiwara, T.; Suzuki, H.; Imai, K.; Shimomura, Y.; Tokino, T.; Kannagi, R.; Dohi, T. DNA hypermethylation contributes to incomplete synthesis of carbohydrate determinants in gastrointestinal cancer. *Gastroenterology* 2008, 135, 142–151. [CrossRef]

55. Kim, Y.S.; Deng, G. Aberrant expression of carbohydrate antigens in cancer: The role of genetic and epigenetic regulation. *Gastroenterology* 2008, 135, 305–309. [CrossRef]

56. Kominato, Y.; Hata, Y.; Takizawa, H.; Matsumoto, K.; Yasui, K.; Tsukada, J.; Yamamoto, F. Alternative promoter identified between a hypermethylated upstream region of repetitive elements and a CpG island in human ABO histo-blood group genes. *J. Biol. Chem.* 2002, 277, 37936–37948. [CrossRef]

57. Kominato, Y.; Hata, Y.; Takizawa, H.; Matsumoto, K.; Yasui, K.; Tsukada, J.; Yamamoto, F. Alternative promoter identified between a hypermethylated upstream region of repetitive elements and a CpG island in human ABO histo-blood group genes. *J. Biol. Chem.* 2002, 277, 37936–37948. [CrossRef]

58. Miyazaki, K.; Ohmori, K.; Izawa, M.; Koike, T.; Kamamoto, K.; Furukawa, K.; Ando, T.; Kiso, M.; Yamaji, T.; Hashimoto, Y.; et al. Loss of disialyl Lewis(a), the ligand for lymphocyte inhibitory receptor sialic acid-binding immunoglobulin-like lectin-(7) (Siglec-7) associated with increased sialyl Lewis(a) expression on human colon cancers. *Cancer Res.* 2004, 64, 4498–4505. [CrossRef]

59. Jacinto, F.V.; Ballestar, E.; Esteller, M. Impaired recruitment of the histone methyltransferase DOT1L contributes to the incomplete reactivation of tumor suppressor genes upon DNA demethylation. *Oncogene* 2009, 28, 4212–4224. [CrossRef]
60. Si, J.; Boumber, Y.A.; Shu, J.; Qin, T.; Ahmed, S.; He, R.; Jelinek, J.; Issa, J.P. Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation. *Cancer Res.* 2010, 70, 6966–6977. [CrossRef] [PubMed]

61. Fang, T.; Lv, H.; Lv, G.; Li, T.; Wang, C.; Han, Q.; Yu, L.; Su, B.; Guo, L.; Huang, S.; et al. Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. *Nat. Commun.* 2018, 9, 191. [CrossRef] [PubMed]

62. Liu, H.; Chen, D.; Bi, J.; Han, J.; Yang, M.; Dong, W.; Lin, T.; Huang, J. Circular RNA circUBXN7 represses cell growth and invasion by sponging miR-1247-3p to enhance B4GALT3 expression in bladder cancer. *Aging* 2018, 10, 2606–2623. [CrossRef] [PubMed]

63. Shan, Y.; Ma, J.; Pan, Y.; Hu, J.; Liu, B.; Jia, L. LncRNA SNHG7 sponges miR-216b to promote proliferation and liver metastasis of colorectal cancer through upregulating GALNT1. *Cell Death Dis.* 2018, 9, 722. [CrossRef] [PubMed]

64. Liu, B.; Pan, S.; Xiao, Y.; Liu, Q.; Xu, J.; Jia, L. LINC01296/miR-26a/GALNT3 axis contributes to colorectal cancer progression by regulating O-glycosylated MUC1 via PI3K/ACK pathway. *J. Exp. Clin. Cancer Res.* 2018, 37, 316. [CrossRef]

65. Qu, J.J.; Qu, X.Y.; Zhou, D.Z. miR4262 inhibits colon cancer cell proliferation via targeting of GALNT4. *Mol. Med. Rep.* 2017, 16, 3731–3736. [CrossRef]

66. Cao, Q.; Wang, N.; Ren, L.; Tian, J.; Yang, S.; Cheng, H. miR-125a-5p post-transcriptionally suppresses GALNT7 to inhibit proliferation and invasion in cervical cancer cells via the EGFR/PI3K/ACK pathway. *Cancer Cell Int.* 2020, 20, 117. [CrossRef]

67. Li, C.; Shi, J.; Zhao, Y. MiR-320 promotes B cell proliferation and the production of aberrant glycosylated IgA1 in IgA nephropathy. *J. Cell Biochem.* 2018, 119, 4607–4614. [CrossRef]

68. Niu, J.T.; Zhang, L.J.; Huang, Y.W.; Li, C.; Jiang, N.; Niu, Y.J. MiR-154 inhibits the growth of laryngeal squamous cell carcinoma by sponging miR-200a to promote O-glycoylation. *Biomed. Pharmacother.* 2020, 128, 110230. [CrossRef] [PubMed]

69. Wu, H.; Chen, J.; Li, D.; Liu, X.; Li, L.; Wang, K. MicroRNA-30e Functions as a Tumor Suppressor in Cervical Carcinoma Cells. *Int. J. Mol. Sci.* 2021, 22, 2980. [CrossRef]

70. Pu, J.; Shen, J.; Zhong, Z.; Yanling, M.; Gao, J. KANK1 regulates paclitaxel resistance in lung adenocarcinoma A549 cells. *Aging* 2018, 10, 4607–4614. [CrossRef] [PubMed]

71. Banerjee, A.; Mahata, B.; Dhir, A.; Mandal, T.K.; Biswas, K. Elevated histone H3 acetylation and loss of the Sp1-HDAC1 complex de-repress the GM2-synthase gene in renal cell carcinoma. *J. Biol. Chem.* 2019, 294, 1005–1018. [CrossRef]

72. Sun, X.J.; Wang, M.C.; Zhang, F.H.; Kong, X. An integrated analysis of genome-wide DNA methylation and gene expression data of colorectal cancer tissue and liquid biopsies. *Mol. Oncol.* 2020, 14, 91–103. [CrossRef] [PubMed]

73. Shankar, S.; Han, D.L.; Wang, L.L.; Zhang, G.F.; Yang, W.F.; Chai, J.; Lin, H.M.; Fu, Z.; Yu, J.M. MiRNA-485-5p, inhibits esophageal cancer cells invasion and protein O-GlcNAcylation by targeting OGT. *Biochem. Cell Biol.* 2018, 96, 752–760. [CrossRef]

74. Chai, Y.; Du, Y.; Zhang, S.; Xiao, J.; Luo, Z.; He, F.; Huang, K. MicroRNA-485-5p Functions as a Tumor Suppressor in Cervical Carcinoma Cells via Targeting ST6GALNAC2 and PI3K/AKT Pathway. *Cancer Cell Int.* 2017, 17, 876–885. [CrossRef] [PubMed]

75. Li, X.; Han, J.; Xue, W.; Jia, L. ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies. *Neoplasma* 2018, 65, 406–414. [CrossRef] [PubMed]

76. Wu, L.; Ning, W.; Jiang, Y.; Zhang, X.; Zhang, X.; Xiao, Y.; Pan, S.; Zhou, H.; Dong, W.; Jia, L. The regulatory ZFAS1/miR-150/ST6GAL1 crosstalk regulates colorectal cancer proliferation and invasion by down-regulating O-linked N-acetylglucosamine transferase. *Eur. Rev. Med. Pharmacol. Sci.* 2018, 22, 372. [CrossRef]

77. Liu, Y.; Huang, H.; Yao, Z.; Chen, Y.; Bai, J.; Gao, H. MiR-150 inhibit HCC proliferation and invasion by targeting betagalactoside alpha-2,6-sialyltransferase 1. *Biochem. Biophys. Res. Commun.* 2018, 505, 745–751. [CrossRef] [PubMed]

78. Wang, L.; Ma, H.; Sun, X.; Liu, B.; Xiao, Y.; Pan, S.; Zhou, H.; Dong, W.; Jia, L. The regulatory ZFAS1/miR-150/ST6GAL1 crosstalk regulates colorectal cancer proliferation and invasion by down-regulating O-linked N-acetylglucosamine transferase. *Eur. Rev. Med. Pharmacol. Sci.* 2018, 22, 372. [CrossRef]

79. Wei, Y.; Shao, J.; Wang, Y.; Shen, H.; Yu, S.; Zhang, J.; Yin, L. Hsa-miR-370 inhibited P-selectin-induced cell adhesion in human colon adenocarcinoma cells. *Mol. Cell. Biochem.* 2019, 450, 159–166. [CrossRef] [PubMed]

80. Han, Y.; Liu, Y.; Fu, X.; Zhang, Q.; Huang, H.; Zhang, C.; Li, W.; Zhang, J. miR-9 inhibits the metastatic ability of hepatocellular carcinoma via targeting beta galactoside alpha-2,6-sialyltransferase 1. *J. Physiol. Biochem.* 2018, 74, 491–501. [CrossRef]

81. Liu, B.; Liu, Q.; Pan, S.; Huang, Y.; Qi, Y.; Li, S.; Xiao, Y.; Jia, L. The HOTAIR/miR-214/ST6GAL1 crosstalk modulates colorectal cancer progression through sialylated c-Met via JAK2/STAT3 cascade. *J. Exp. Clin. Cancer Res.* 2019, 38, 455. [CrossRef]

82. Liu, Q.; Ma, H.; Sun, X.; Liu, B.; Xiao, Y.; Pan, S.; Zhou, H.; Dong, W.; Jia, L. The regulatory ZFAS1/miR-150/ST6GAL1 crosstalk modulates sialylation of EGFR via PI3K/Akt pathway in T-cell acute lymphoblastic leukemia. *J. Exp. Clin. Cancer Res.* 2019, 38, 199. [CrossRef]

83. Liang, L.; Xu, J.; Wang, M.; Xu, G.; Zhang, N.; Wang, G.; Zhao, Y. LncRNA HCP5 promotes follicular thyroid carcinoma progression via miRNAs sponge. *Cell Death Dis.* 2018, 9, 372. [CrossRef]

84. Jia, L.; Luo, S.; Ren, X.; Li, Y.; Hu, J.; Liu, B.; Zhao, L.; Shan, Y.; Zhou, H. miR-182 and miR-135b Mediate the Tumorigenesis and Progression via miRNAs sponge. *Cell Death Dis.* 2020, 11, 639–647. [CrossRef] [PubMed]

85. Haldrup, C.; Pedersen, A.L.; Ogaard, N.; Strand, S.H.; Hoyer, B.; Borre, M.; Orntoft, T.F.; Sorensen, K.D. Biomarker potential of ST6GALNAc3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies. *Mol. Oncol.* 2018, 12, 545–560. [CrossRef]
86. Verlaat, W.; Snoek, B.C.; Heideman, D.A.M.; Wilting, S.M.; Snijders, P.J.F.; Noviandi, P.W.; van Splunter, A.P.; Peeters, C.F.W.; van Trommel, N.E.; Massuger, L.; et al. Identification and Validation of a 3-Gene Methylation Classifier for HPV-Based Cervical Screening on Self-Samples. *Clin. Cancer Res.* 2018, 24, 3456–3464. [CrossRef]

87. Huang, H.C.; Chao, C.C.; Wu, P.H.; Chung, H.Y.; Lee, H.Y.; Suen, C.S.; Hwang, M.J.; Cai, B.H.; Kannagi, R. Epigenetic silencing of the synthesis of immunosuppressive Siglec ligand glycans by NF-kappaB/EZH2/YY1 axis in early-stage colon cancers. *Biochim. Biophys. Acta Gen. Revi. 2019*, 1862, 173–183. [CrossRef] [PubMed]

88. Li, W.; Zheng, X.; Ren, L.; Fu, W.; Liu, J.; Xu, J.; Liu, S.; Wang, J.; Du, G. Epigenetic hypomethylation and upregulation of GD3s in triple negative breast cancer. *Ann. Transl. Med.* 2019, 7, 723. [CrossRef] [PubMed]

89. Qin, Y.; Wu, C.W.; Taylor, W.R.; Sawas, T.; Burger, K.N.; Mahoney, D.W.; Sun, Z.; Yab, T.C.; Lidgard, G.P.; Allawi, H.T.; et al. Discovery, Validation, and Application of Novel Methylated DNA Markers for Detection of Esophageal Cancer in Plasma. *Clin. Cancer Res.* 2019, 25, 7396–7404. [CrossRef] [PubMed]

90. Shang, Y.; Liu, Y.; Zhao, L.; Liu, B.; Li, Y.; Jia, L. MicroRNA-33a and let-7e inhibit human colorectal cancer progression by targeting ST8SIA1. *Int. J. Biochem. Cell Biol.* 2017, 90, 48–58. [CrossRef]

91. Ma, W.; Zhao, X.; Liang, L.; Wang, G.; Li, Y.; Miao, X.; Zhao, Y. miR-146e and miR-146b promote proliferation, migration and invasion of follicular thyroid carcinoma via inhibition of ST8SIA4. *Oncotarget* 2017, 8, 28028–28041. [CrossRef] [PubMed]

92. Wang, F.; Ye, L.J.; Wang, F.J.; Liu, H.F.; Wang, X.L. miR-146a promotes proliferation, invasion, and epithelial-to-mesenchymal transition in oral squamous carcinoma cells. *Environ. Toxicol.* 2020, 35, 1050–1057. [CrossRef]

93. Wang, Y.; Chen, J.; Chen, X.; Jiang, F.; Sun, Y.; Pan, Y.; Zhang, W.; Zhang, J. MiR-34a suppresses HNSCC growth through modulating cell cycle arrest and senescence. *Neoplasma* 2017, 64, 543–553. [CrossRef]

94. Li, W.; Li, Y.; Ma, W.; Zhou, J.; Sun, Z.; Yan, X. Long noncoding RNA AC14812.8 promotes the progression of bladder cancer through miR-371b-5p/FUT4 axis. *Biomed. Pharmacother.* 2020, 121, 109605. [CrossRef]

95. Li, Y.; Sun, Z.; Liu, B.; Shan, Y.; Zhao, L.; Jia, L. Tumor-suppressive miR-26a and miR-26b inhibit cell aggressiveness by regulating FUT4 in colorectal cancer. *Cell Death Dis.* 2018, 9, e8292. [CrossRef]

96. Liu, B.; Ma, H.; Liu, Q.; Xia, Y.; Pan, S.; Zhou, H.; Jia, L. MiR-29b/Sp1/FUT4 axis modulates the malignancy of leukemia stem cells by regulating fucosylation via Wnt/beta-catenin pathway in acute myeloid leukemia. *J. Exp. Clin. Cancer Res.* 2019, 38, 200. [CrossRef]

97. Yuan, X.; Liu, J.; Ye, X. Effect of miR-200c on proliferation and invasion of breast cancer cells and relevant mechanisms. *J. Buon.* 2019, 24, 61–67.

98. Zhang, C.; Ge, C. A Simple Competing Endogenous RNA Network Identifies Novel mRNA, miRNA, and IncRNA Markers in Human Cholangiocarcinoma. *Biomed. Res. Int.* 2019, 2019, 3526407. [CrossRef] [PubMed]

99. Zhang, Y.; Zhang, D.; Lv, J.; Wang, S.; Zhang, Q. MiR-125a-5p suppresses bladder cancer progression through targeting FUT4. *Biomed. Pharmacother.* 2018, 108, 1039–1047. [CrossRef]

100. Zheng, Q.; Cui, X.; Zhang, D.; Yang, Y.; Yan, X.; Liu, M.; Niang, B.; Aziz, F.; Liu, S.; Yan, Q.; et al. miR-200b inhibits proliferation and metastasis of breast cancer by targeting fucosyltransferase IV and alpha1-3-fucosylated glycans. *Oncogenesis* 2017, 6, e358. [CrossRef] [PubMed]

101. Liang, L.; Gao, C.; Li, Y.; Sun, M.; Xu, J.; Li, H.; Jia, L.; Zhao, Y. miR-125a-3p/FUT5-FUT6 axis mediates colorectal cancer cell proliferation, migration, invasion and pathological angiogenesis via PI3K-Akt pathway. *Cell Death Dis.* 2017, 8, e2968. [CrossRef]

102. Pan, S.; Liu, Y.; Liu, Q.; Xiao, Y.; Liu, B.; Ren, X.; Qi, X.; Zhou, H.; Zeng, C.; Jia, L. HOTAIR/miR-326/FUT4 axis facilitates colorectal cancer progression through regulating fucosylation of CD44 via PI3K/AKT/mTOR pathway. *Biochim. Biophys. Acta Mol. Cell Res.* 2019, 1866, 750–760. [CrossRef]

103. Zhang, Z.L.; Jiang, H.Y.; Wang, Y.S.; Shi, M.H. Heparan sulfate D-glucosamine 3-O-sulfotransferase 3B1 is a novel regulator of transforming growth factor-beta-mediated epithelial-to-mesenchymal transition and regulated by miR-218 in nonsmall cell lung cancer. *J. Cancer Res. Ther.* 2018, 14, 24–29. [CrossRef]

104. Oliveira-Ferrer, L.; Legler, K.; Milde-Langosch, K. Role of protein glycosylation in cancer metastasis. *Semin. Cancer Biol.* 2017, 44, 141–152. [CrossRef]

105. Schietinger, A.; Philip, M.; Yoshida, B.A.; Azadi, P.; Liu, H.; Meredith, S.C.; Schreiber, H. A mutant chaperone converts a wild-type protein into a tumor-specific antigen. *Science* 2006, 314, 304–308. [CrossRef]

106. Mi, R.; Song, L.; Wang, Y.; Ding, X.; Zeng, J.; Lehoux, S.; Aryal, R.P.; Wang, J.; Crew, V.K.; van Die, I.; et al. Epigenetic silencing of the chaperone Cosmic in human leukocytes expressing tn antigen. *J. Biol. Chem.* 2012, 287, 41523–41533. [CrossRef]

107. Xu, F.; Wang, D.; Cui, J.; Li, J.; Jiang, H. Demethylation of the Cosmic Promoter Alleviates the Progression of Breast Cancer Through Downregulation of the Tn and Sialyl-Tn Antigens. *Cancer Manag. Res.* 2020, 12, 1017–1027. [CrossRef]

108. Fuster, M.M.; Esko, J.D. The sweet and sour of cancer: Glycans as novel therapeutic targets. *Nat. Rev. Cancer* 2005, 5, 526–542. [CrossRef] [PubMed]

109. Julien, S.; Krzewinski-Recchi, M.A.; Harduin-Lepers, A.; Gouyer, V.; Huet, G.; Le Bourhis, X.; Delannoy, P. Expression of sialyl-Tn antigen in breast cancer tissues transfected with the human CMP-Neu5Ac: GalNAc alpha2,6-sialyltransferase (ST6GalNac I) cDNA. *Glycoconj. J.* 2001, 18, 883–893. [CrossRef]

110. Dall’Olio, F.; Malagolini, N.; Chiricolo, M.; Trinchera, M.; Harduin-Lepers, A. The expanding roles of the Sd(a)/Cad carbohydrate antigen and its cognate glycosyltransferase B4GALNT2. *Biochim. Biophys. Acta* 2014, 1840, 443–453. [CrossRef] [PubMed]

111. Ravn, V.; Dablesteen, E. Tissue distribution of histo-blood group antigens. *APMIS* 2000, 108, 1–28. [CrossRef]
112. Wang, H.R.; Hsieh, C.Y.; Twu, Y.C.; Yu, L.C. Expression of the human Sd(a) beta-1,4-N-acetylgalactosaminyltransferase II gene is dependent on the promoter methylation status. *Glycobiole* 2008, 18, 104–113. [CrossRef] [PubMed]

113. Ginsburg, D. Identifying novel genetic determinants of hemostatic balance. *J. Thromb. Haemost.* 2005, 3, 1561–1568. [CrossRef] [PubMed]

114. Mohlike, K.L.; Purkayastha, A.A.; Westrick, R.J.; Smith, P.L.; Petryniak, B.; Lowe, J.B.; Ginsburg, D. Mvwf, a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase. *Cell* 1999, 96, 111–120. [CrossRef]

115. Li, P.T.; Liao, C.J.; Wu, W.G.; Yu, L.C.; Chu, S.T. Progesterone-regulated B4galnt2 expression is a requirement for embryo implantation in mice. *Fertil. Steril.* 2011, 95, 2404–2409.e3. [CrossRef]

116. Malagolini, N.; Santini, D.; Chiricolo, M.; Dall’olio, F. Biosynthesis and expression of the Sda and sialyl Lewis X antigens in normal and cancer colon. *Glycobiology* 2007, 17, 688–697. [CrossRef]

117. Kawamura, Y.I.; Kawashima, R.; Fukunaga, R.; Hirai, K.; Toyama-Sorimachi, N.; Tokuhara, M.; Shimizu, T.; Dohi, T. Introduction of Sda carbohydrate antigen in gastrointestinal cancer cells eliminates selectin ligands and inhibits metastasis. *Cancer Res.* 2005, 65, 6220–6227. [CrossRef]

118. Dall’olio, F.; Malagolini, N.; Serafini-Cessi, F. Tissue distribution and age-dependent expression of beta-4-N-acetylgalactosaminyltransferase in guinea-pig. *Biochi. Rep.* 1987, 7, 925–932. [CrossRef]

119. Dall’olio, F.; Malagolini, N.; Di Stefano, G.; Ciambella, M.; Serafini-Cessi, F. Postnatal development of rat colon epithelial cells is associated with changes in the expression of the beta 1,4-N-acetylgalactosaminyltransferase involved in the synthesis of Sda antigen of alpha 2,6-sialyltransferase activity towards N-acetyl-lactosamine. *Biochem. J.* 1990, 270, 519–524. [CrossRef] [PubMed]

120. Malagolini, N.; Santini, D.; Chiricolo, M.; Dall’olio, F. Biosynthesis and expression of the Sda and sialyl Lewis x antigens in normal and cancer colon. *Glycobiology* 2007, 17, 688–697. [CrossRef]

121. Groux-Degroote, S.; Wavelet, C.; Krzewinski-Recchi, M.A.; Portier, L.; Mortuaire, M.; Mihalache, A.; Trinchera, M.; Delannoy, P.; Malagolini, N.; Chiricolo, M.; et al. B4GALNT2 gene expression controls the biosynthesis of Sda and sialyl Lewis X antigens in healthy and cancer human gastrointestinal tract. *Int. J. Biochem. Cell Biol.* 2014, 53, 442–449. [CrossRef]

122. Zoldos, V.; Grgurevic, S.; Lau, G. Epigenetic regulation of protein glycosylation. *Biomol. Concepts* 2010, 1, 253–261. [CrossRef] [PubMed]

123. Indelicato, R.; Zuluetta, A.; Caretti, A.; Trinchera, M. Complementary Use of Carbohydrate Antigens Lewis a, Lewis b, and Sialyl-Lewis a, Lewis b, and Sialyl-Lewis x Antigens in Gastrointestinal Cancers: Biological Rationale Towards A Personalized Clinical Application. *Cancers* 2020, 12, 1509. [CrossRef] [PubMed]

124. Trinchera, M.; Zuluetta, A.; Caretti, A.; Dall’olio, F. Control of Glycosylation-Related Genes by DNA Methylation: The Intriguing Case of the B3GALT5 Gene and Its Distinct Promoters. *Biology* 2014, 3, 484–497. [CrossRef] [PubMed]

125. Holgersson, J.; Lofling, J. Glycosyltransferases involved in type 1 chain Lewis antigen biosynthesis exhibit glycan and core chain specificity. *Glycobiology* 2006, 16, 584–593. [CrossRef] [PubMed]

126. Chase, S.D.; Magnani, J.L.; Simon, S.I. E-selectin ligands as mechanosensitive receptors on neutrophils in health and disease. *Ann. Biomed. Eng.* 2012, 40, 849–859. [CrossRef]

127. Malagolini, N.; Chiricolo, M.; et al. B4GALNT2 gene expression controls the biosynthesis of Sda and sialyl Lewis X antigens in healthy and cancer human gastrointestinal tract. *Int. J. Biochem. Cell Biol.* 2014, 53, 442–449. [CrossRef]

128. Dunn, C.A.; van de Lagemaat, L.N.; Baillie, G.J.; Mager, D.L. Endogenous retrovirus long terminal repeats as ready-to-use mobile promoters: The case of primate beta3GAL-T5. *Gene* 2005, 366, 326–12. [CrossRef] [PubMed]

129. Dunn, C.A.; Medstrand, P.; Mager, D.L. An endogenous retroviral long terminal repeat is the dominant promoter for human beta1,3-galactosyltransferase 5 in the colon. *Proc. Natl. Acad. Sci. USA* 2003, 100, 12841–12846. [CrossRef]

130. Zuluetta, A.; Caretti, A.; Signorelli, P.; Dall’olio, F.; Trinchera, M. Transcriptional control of the B3GALT5 gene by a retroviral promoter: The case of primate beta3GAL-T5. *Gene* 2005, 366, 326–12. [CrossRef] [PubMed]

131. Aronica, A.; Avagliano, L.; Caretti, A.; Tosi, D.; Bulfamante, G.P.; Trinchera, M. Unexpected distribution of CA19.9 and other glycobiology of human colon adenocarcinomas. *J. Biol. Chem.* 2001, 276, 3564–3573. [CrossRef] [PubMed]

132. Abraham, C.; Cho, J.H. Inflammatory bowel disease. *N. Engl. J. Med.* 2009, 361, 2066–2078. [CrossRef] [PubMed]

133. Isshiki, S.; Kudo, T.; Nishihara, S.; Ikehara, Y.; Topgach, A.; Furuya, A.; Shirata, K.; Kubota, T.; Watanabe, M.; Kitajima, M.; et al. Lewis type 1 antigen synthase (beta3Gal-T5) is transcriptionally regulated by homeoproteins. *J. Biol. Chem.* 2003, 278, 36611–36620. [CrossRef]
137. Borg-Bartolo, S.P.; Boyapati, R.K.; Satsangi, J.; Kalla, R. Precision medicine in inflammatory bowel disease: Concept, progress and challenges. *F1000Research* 2020, 9. [CrossRef] [PubMed]

138. Gonsky, R.; Deen, R.L.; Targan, S.R. Distinct Methylation of IFNG in the Gut. *J. Interferon Cytokine Res.* 2009, 29, 407–414. [CrossRef]

139. Lobaton, T.; Azuara, D.; Rodriguez-Moranta, F.; Loayza, C.; Sanjuan, X.; de Oca, J.; Fernandez-Robles, A.; Guardiola, J.; Capella, G. Relationship between methylation and colonic inflammation in inflammatory bowel disease. *World J. Gastroenterol.* 2014, 20, 10591–10598. [CrossRef] [PubMed]

140. Saito, S.; Kato, J.; Hiraoka, S.; Horii, J.; Suzuki, H.; Higashi, R.; Kaji, E.; Kondo, Y.; Yamamoto, K. DNA methylation of colon mucosa in ulcerative colitis patients: Correlation with inflammatory status. *Inflamm. Bowel Dis.* 2011, 17, 1955–1965. [CrossRef]

141. Tahara, T.; Shibata, T.; Nakamura, M.; Yamashita, H.; Yoshioka, D.; Okubo, M.; Maruyama, N.; Kamano, T.; Kamiya, Y.; Fujita, H.; et al. Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC). *Clin. Exp. Med.* 2009, 9, 125–130. [CrossRef]

142. Tahara, T.; Shibata, T.; Nakamura, M.; Yamashita, H.; Yoshioka, D.; Okubo, M.; Maruyama, N.; Kamano, T.; Kamiya, Y.; Nakagawa, Y.; et al. Effect of MDRI gene promoter methylation in patients with ulcerative colitis. *Int. J. Mol. Med.* 2009, 23, 521–527. [CrossRef]

143. Cooke, J.; Zhang, H.; Greger, L.; Silva, A.L.; Massey, D.; Dawson, C.; Metz, A.; Ibrahim, A.; Parkes, M. Mucosal genome-wide methylation changes in inflammatory bowel disease. *Inflamm. Bowel Dis.* 2012, 18, 2128–2137. [CrossRef]

144. Hasler, R.; Feng, Z.; Backdahl, L.; Spehlmann, M.E.; Franke, A.; Teschendorff, A.; Rakyan, V.K.; Down, T.A.; Wilson, G.A.; Feber, A.; et al. A functional methylome map of ulcerative colitis. *Genome Res.* 2012, 22, 2130–2137. [CrossRef] [PubMed]

145. Karatzas, P.S.; Mantzaris, G.J.; Safioleas, M.; Gazouli, M. DNA methylation profile of genes involved in inflammation and autoimmunity in inflammatory bowel disease. *Medicine (Baltimore)* 2014, 93, e309. [CrossRef] [PubMed]

146. Nimmo, E.R.; Prendergast, J.G.; Kennedy, N.A.; Henderson, P.; Drummond, H.E.; Ramsahoye, B.H.; Wilson, D.C.; Semple, C.A.; Satsangi, J. Genome-wide methylation profiling in Crohn’s disease identifies altered epigenetic regulation of key host defense mechanisms including the Th17 pathway. *Inflamm. Bowel Dis.* 2012, 18, 889–899. [CrossRef]

147. Mateos, B.; Palanca-Ballester, C.; Saez-Gonzalez, E.; Moret, I.; Lopez, A.; Sandovial, J. Epigenetics of Inflammatory Bowel Disease: Unraveling Pathogenic Events. *Croh’s Colitis 360* 2019, 1. [CrossRef]

148. Klasic, M.; Markulin, D.; Vojta, A.; Samarzija, I.; Birus, I.; Dobrinic, P.; Venthman, N.T.; Trbojevic-Akmac, I.; Simurina, M.; Stambuk, J.; et al. Promoter methylation of the MGAT3 and BACH2 genes correlates with the composition of the immunoglobulin G glycome in inflammatory bowel disease. *Clin. Epigenet.* 2018, 10, 75. [CrossRef] [PubMed]

149. Serino, G.; Sallustio, F.; Cox, S.N.; Pesce, F.; Schena, F.P. Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy. *J. Am. Soc. Nephrol.* 2012, 23, 814–824. [CrossRef] [PubMed]

150. Serino, G.; Sallustio, F.; Curci, C.; Cox, S.N.; Pesce, F.; De Palma, G.; Schena, F.P. Role of let-7b in the regulation of N-acetylgalactosaminyltransferase 2 in IgA nephropathy. *Nephrol. Dial Transplant.* 2015, 30, 1132–1139. [CrossRef]

151. Liu, D.; Xia, M.; Liu, Y.; Tan, X.; He, L.; Chen, G.; Liu, H. The upregulation of miR-98-5p affects the glycosylation of IgA1 through cytokines in IgA nephropathy. *Int. Immunopharmacol.* 2020, 82, 106362. [CrossRef] [PubMed]

152. Hu, S.; Bao, H.; Xu, X.; Zhou, X.; Qin, W.; Zeng, C.; Liu, Z. Increased miR-374b promotes cell proliferation and the production of aberrant glycosylated IgA1 in B cells of IgA nephropathy. *FEBS Lett.* 2015, 589, 4019–4025. [CrossRef] [PubMed]

153. Moll, T.; Shaw, P.J.; Cooper-Knock, J. Disrupted glycosylation of lipids and proteins is a cause of neurodegeneration. *Brain* 2020, 143, 1332–1340. [CrossRef]

154. Trinchera, M.; Parini, R.; Indelicato, R.; Domenighini, R.; dall’Olio, F. Diseases of ganglioside biosynthesis: An expanding group of congenital disorders of glycosylation. *Mol. Genet. Metab.* 2018, 124, 230–237. [CrossRef]

155. Zulueta, A.; Mingione, A.; Signorelli, P.; Caretti, A.; Ghidoni, R.; Trinchera, M. Simple and Complex Sugars in Parkinson’s Disease: A Bittersweet Taste. *Mol. Neurobiol.* 2019, 57, 2934–2943. [CrossRef] [PubMed]

156. Chao, C.C.; Gutierrez-Vazquez, C.; Rothhammer, V.; Mayo, L.; Wheeler, M.A.; Tjon, E.C.; Zandee, S.E.J.; Blain, M.; de Lima, K.A.; Takenaka, M.C.; et al. Metabolic Control of Astrocyte Pathogenic Activity via cPLA2-MAVS. *F1000Research* 2020, 9, 179. [CrossRef] [PubMed]

157. Ishimoto, S.; Withers, D.A.; Handa, K.; Hakomori, S. Deletion of A-antigen in a human cancer cell line is associated with reduced promoter activity of CBF/NF-Y binding region, and possibly with enhanced DNA methylation of A-transfactor promoter. *Glycoconj. J.* 1999, 16, 659–666. [CrossRef] [PubMed]

158. Pink, M.; Ratsch, B.A.; Mardahl, M.; Schroter, M.F.; Engelbert, D.; Triebus, J.; Hamann, A.; Syrbe, U. Identification of two regulatory elements controlling Fucosyltransferase 7 transcription in murine CD4+ T cells. *Mol. Immunol.* 2014, 62, 1–9. [CrossRef] [PubMed]

159. Syrbe, U.; Jennrich, S.; Schottelius, A.; Richter, A.; Radbruch, A.; Hamann, A. Differential regulation of P-selectin ligand expression in naive versus memory CD4+ T cells: Evidence for epigenetic regulation of involved glycosyltransferase genes. *Blood* 2004, 104, 3243–3248. [CrossRef] [PubMed]